

# Christian P Selinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8149494/publications.pdf>

Version: 2024-02-01

162  
papers

5,687  
citations

126907

33  
h-index

85541

71  
g-index

164  
all docs

164  
docs citations

164  
times ranked

5797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. <i>Gut</i> , 2023, 72, 410-412.	12.1	5
2	Managing Inflammatory Bowel Disease in Pregnancy: Health Care Professionals'™ Involvement, Knowledge, and Decision Making. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 522-530.	1.9	4
3	Adapting "Tame Your Gut"™ for patients with inflammatory bowel disease and co-morbid anxiety and/or depression. <i>Journal of Health Psychology</i> , 2022, 27, 58-68.	2.3	2
4	Risk stratifying gastric ulcers: development and validation of a scoring system. <i>Frontline Gastroenterology</i> , 2022, 13, flgastro-2020-101759.	1.8	2
5	Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2022, 13, 77-81.	1.8	2
6	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14256.	3.0	6
7	Gastroenterology team members'™ knowledge and practices with fertility therapy for women with inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210875.	3.2	3
8	Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease™ authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1070-1071.	3.7	0
9	Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. <i>Frontline Gastroenterology</i> , 2022, 13, 490-496.	1.8	2
10	A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's™ disease. The Cross Pennine study II. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 856-866.	3.7	17
11	Editorial: choosing the optimal screening method for latent <i>TB</i> in patients with <i>IBD</i> commencing <i>anti-TNF</i> therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1346-1347.	3.7	1
12	Using the PIDA on Your PDA: Providing Personalized Education and Decision Support for Women with IBD of Childbearing Age. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4315-4316.	2.3	3
13	The source of individual heterogeneity shapes infectious disease outbreaks. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2022, 289, 20220232.	2.6	3
14	Risk of Adverse Pregnancy Outcomes for Women with IBD in an Expert IBD Antenatal Clinic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2919.	2.4	5
15	Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of <i>UK IBD</i> units and patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 625-645.	3.7	12
16	Understanding <i>anti-TNF</i> treatment failure: does serum triiodothyronine-to-thyroxine ( <i>T3</i> / <i>T4</i> ) ratio predict therapeutic outcome to <i>anti-TNF</i> therapies in biologic-naïve patients with active luminal Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 783-793.	3.7	5
17	Utility of Fecal Calprotectin in Routine Clinical Practice Is Impaired by Poor Sample Return Rates. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3209-3210.	2.3	2
18	Lived experience in people with inflammatory bowel disease and comorbid anxiety and depression in the United Kingdom and Australia. <i>Journal of Health Psychology</i> , 2021, 26, 2290-2303.	2.3	13

#	ARTICLE	IF	CITATIONS
19	Steroid use and misuse: a key performance indicator in the management of IBD. <i>Frontline Gastroenterology</i> , 2021, 12, 207-213.	1.8	11
20	IBD in pregnancy: recent advances, practical management. <i>Frontline Gastroenterology</i> , 2021, 12, 214-224.	1.8	27
21	Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society. <i>Frontline Gastroenterology</i> , 2021, 12, 182-187.	1.8	26
22	Acceptability of a "treat to target"™ approach in inflammatory bowel disease to patients in clinical remission. <i>Frontline Gastroenterology</i> , 2021, 12, 30-38.	1.8	7
23	Patients'™ perception of colonoscopy and acceptance of colonoscopy based IBD related colorectal cancer surveillance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 211-216.	3.0	5
24	Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. <i>Rheumatology</i> , 2021, 60, 467-470.	1.9	1
25	Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 111-119.	3.1	1
26	Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1091-1096.	3.0	15
27	Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000603.	2.7	8
28	Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. <i>Internal and Emergency Medicine</i> , 2021, 16, 1433-1442.	2.0	5
29	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153
30	Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1524-1532.	1.6	6
31	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	8.1	111
32	Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON® Gold Testing Useful?. <i>Journal of Clinical Medicine</i> , 2021, 10, 1816.	2.4	3
33	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	8.1	23
34	Optimizing the early detection of low pathogenic avian influenza H7N9 virus in live bird markets. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20210074.	3.4	5
35	A "real-world"™ retrospective multi-centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis. <i>GastroHep</i> , 2021, 3, 229-235.	0.6	1
36	Perineal Outcomes After Delivery in 179 Mothers with Inflammatory Bowel Disease Compared to 31 258 Controls: A Single-Centre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, , .	1.3	5

#	ARTICLE	IF	CITATIONS
37	Reconstructing contact network structure and cross-immunity patterns from multiple infection histories. <i>PLoS Computational Biology</i> , 2021, 17, e1009375.	3.2	1
38	Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4329.	2.4	2
39	Episome partitioning and symmetric cell divisions: Quantifying the role of random events in the persistence of HPV infections. <i>PLoS Computational Biology</i> , 2021, 17, e1009352.	3.2	2
40	Predicting COVID-19 incidence in French hospitals using human contact network analytics. <i>International Journal of Infectious Diseases</i> , 2021, 111, 100-107.	3.3	9
41	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 132-139.	1.9	1
42	Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 987-988.	8.1	12
43	Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. <i>United European Gastroenterology Journal</i> , 2021, 9, 1136-1147.	3.8	24
44	Provision of care for pregnant women with IBD in the UK: the current landscape. <i>Frontline Gastroenterology</i> , 2021, 12, 487-492.	1.8	5
45	Evaluation of Anorectal Function in Perianal Crohn's Disease: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5909.	2.4	1
46	Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 346-347.	3.7	1
47	Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1147-1148.	3.7	1
48	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	1.9	17
49	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	1.3	249
50	Stigmatisation and resilience in inflammatory bowel disease. <i>Internal and Emergency Medicine</i> , 2020, 15, 211-223.	2.0	26
51	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	8.1	108
52	Re: Roberti R, Iannone LF, Palleria C, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Curr Med Res Opin</i> . 2020. DOI:10.1080/03007995.2020.1786681. <i>Current Medical Research and Opinion</i> , 2020, 36, 1627-1628.	1.9	0
53	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2020, 11, 343-350.	1.8	37
54	Letter: recognising frailty in patients with inflammatory bowel disease is crucial for appropriate personalised treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 908-909.	3.7	2

#	ARTICLE	IF	CITATIONS
55	The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 191-199.	1.9	3
56	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	12.1	28
57	Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1248-1255.	1.3	27
58	The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1316-1329.	1.3	48
59	Biologics are the main contributor to cost of care for IBD: a European perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 421-422.	8.1	2
60	Letter: increased risk of caesarean section for women with IBD – more questions than answers. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 667-668.	3.7	4
61	Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 915-916.	3.7	2
62	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	12.1	232
63	Gastric Cancer in Patients with Inflammatory Bowel Disease: More than just a Random Association?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 11-12.	0.9	3
64	Assessment of steroid use as a key performance indicator in inflammatory bowel disease – analysis of data from 2385 UK patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1009-1018.	3.7	37
65	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i> , 2019, 68, s1-s106.	12.1	1,353
66	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	8.1	431
67	Current smoking habits in British IBD patients in the age of e-cigarettes. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000309.	2.7	11
68	Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 693-701.	1.3	39
69	Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1390-1398.	1.9	16
70	The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 919-924.	1.9	19
71	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774473.	3.2	18
72	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 700-707.	1.5	35

#	ARTICLE	IF	CITATIONS
73	Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease—Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 145-145.	3.7	0
74	Microbial Preparations (Probiotics) for the Prevention of <i>Clostridium difficile</i> Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 771-781.	1.8	42
75	When Your Pregnancy Echoes Your Illness: Transition to Motherhood With Inflammatory Bowel Disease. <i>Qualitative Health Research</i> , 2018, 28, 1283-1294.	2.1	8
76	OTU-003—Etolizumab as induction therapy in moderate to severe Crohn's disease: results from bergamot cohort 1. , 2018, , .		6
77	ADTU-03—Impact of improved access to biologic therapies and physician engagement on excess steroid exposure. , 2018, , .		0
78	ADTU-06—Real world outcomes of vedolizumab over 12 months: the cross pennine multicentre experience. , 2018, , .		0
79	PTU-007—A retrospective multicentre study comparing infliximab and adalimumab for maintenance of remission in ulcerative colitis. , 2018, , .		0
80	PWE-011—The psychosocial effects of inflammatory bowel disease on reproductive health—a systematic literature review. , 2018, , .		0
81	PWE-055—Current smoking trends in British IBD patients in the age of E-cigarettes. , 2018, , .		0
82	PWE-054—Infliximab therapeutic drug monitoring in IBD virtual biologics clinic leads to durable results. , 2018, , .		0
83	Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1202-1212.	3.7	26
84	The role of biologics in the treatment of patients with inflammatory bowel disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 686-693.	0.5	5
85	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	3.7	24
86	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	8.1	126
87	A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. <i>Digestive and Liver Disease</i> , 2018, 50, 1299-1304.	0.9	44
88	Patients' Beliefs and Concerns About the Necessity of Long-Term Therapies Are Crucial for Medication Adherence for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jiw213.	1.3	10
89	Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-12.	3.0	39
90	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. <i>Frontline Gastroenterology</i> , 2017, 8, 203-209.	1.8	13

#	ARTICLE	IF	CITATIONS
91	Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2083-2088.	1.9	15
92	A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 964-973.	3.7	62
93	Gastrointestinal: Cause or effect: A case of microcytic anemia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1793-1793.	2.8	1
94	Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1257-1261.	1.9	33
95	Female Gender, Somatization and Presence of IBS-Type Symptoms Predicts Dyspareunia in Patients with IBD. <i>Gastroenterology</i> , 2017, 152, S795.	1.3	0
96	Presentation and Surgical Interventions for Crohn's Disease with Perianal Fistula in the Biologics Era: Results from a Multicentre Study. <i>Gastroenterology</i> , 2017, 152, S1282.	1.3	0
97	Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderate-to-Severe Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S1310.	1.3	4
98	Multicentre Cohort Study to Evaluate the Need for Re-Intervention following Multimodal Treatment in Crohn's Disease with Perianal Fistula. <i>Gastroenterology</i> , 2017, 152, S778.	1.3	0
99	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 63-74.	3.7	36
100	Medication adherence in inflammatory bowel disease. <i>Intestinal Research</i> , 2017, 15, 434.	2.6	102
101	Current practice and clinicians' perception of medication non-adherence in patients with inflammatory bowel disease: A survey of 98 clinicians. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017, 8, 67.	1.1	7
102	Effectiveness and Safety of Vedolizumab (VDZ) in IBD Patients: A Multicenter Experience of Real World Data From the U.K.. <i>American Journal of Gastroenterology</i> , 2017, 112, S381.	0.4	0
103	The economics of biological therapy for inflammatory bowel disease and the case for equality. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 650-651.	0.4	1
104	Managing inflammatory bowel disease in pregnancy: current perspectives. <i>Clinical and Experimental Gastroenterology</i> , 2016, Volume 9, 325-335.	2.3	22
105	More than 1842 Excess Steroid Use in IBD: Too Much, How Much and Why? Results From a UK Nationwide Audit. <i>Gastroenterology</i> , 2016, 150, S791.	1.3	0
106	What Factors Might Drive Voluntary Childlessness (VC) in Women with IBD? Does IBD-specific Pregnancy-related Knowledge Matter?. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1151-1158.	1.3	77
107	Gastric ulcers: malignancy yield and risk stratification for follow-up endoscopy. <i>Endoscopy International Open</i> , 2016, 04, E709-E714.	1.8	13
108	SEMS for Palliation of Malignant Colonic Obstruction: Why SEMi Available Is Not Good Enough. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1781-1782.	2.3	0

#	ARTICLE	IF	CITATIONS
109	Pregnancy and inflammatory bowel disease: Do we provide enough patient education? A British study of 1324 women. <i>World Journal of Gastroenterology</i> , 2016, 22, 8219.	3.3	24
110	Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 61-70.	3.7	81
111	Inflammatory bowel disease and anxiety: links, risks, and challenges faced. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 111.	2.3	76
112	Inflammatory bowel disease-specific pregnancy knowledge of gastroenterologists against general practitioners and obstetricians. <i>United European Gastroenterology Journal</i> , 2015, 3, 462-470.	3.8	23
113	The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 107-124.	1.3	369
114	The cost-effectiveness of infliximab in Crohn's disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 589-598.	1.4	7
115	Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 329-334.	3.0	4
116	How costly is non-adherence to infliximab in patients with Crohn's disease?. <i>Journal of Medical Economics</i> , 2014, 17, 881-882.	2.1	2
117	Early Use of Thiopurines or Methotrexate Reduces Major Abdominal and Perianal Surgery in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1382-1390.	1.9	48
118	One size fits all? Choosing the right format to convey statistical information. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1565.	1.3	0
119	Long-term Follow-up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 644-650.	4.4	74
120	Mo1637 Confocal Endomicroscopy Identifies Intestinal Mucosal Barrier Dysfunction in Macroscopically-Normal Crohn's Disease and Ulcerative Colitis. <i>Gastrointestinal Endoscopy</i> , 2013, 77, AB454.	1.0	0
121	205 Intestinal Barrier Dysfunction Measured With Confocal Endomicroscopy in Macroscopically Normal Mucosa Can Predict Requirement for Treatment Escalation. <i>Gastrointestinal Endoscopy</i> , 2013, 77, AB136.	1.0	1
122	Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e214-e218.	1.3	54
123	Inflammatory bowel disease and pregnancy: Lack of knowledge is associated with negative views. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e206-e213.	1.3	146
124	Cancer surveillance for patients with colonic Crohn's disease: will your patients benefit?. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e714.	1.3	0
125	Conveying medication benefits to ulcerative colitis patients and effects on patient attitudes regarding thresholds for adherence. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e312-e317.	1.3	4
126	Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. <i>Journal of Hospital Infection</i> , 2013, 84, 159-165.	2.9	78



#	ARTICLE	IF	CITATIONS
127	Commentary: 5-ASA switches in IBD, adherence and flares. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1138-1138.	3.7	2
128	Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2199-2206.	1.9	102
129	Cause-Specific Mortality and 30-year Relative Survival of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	36
130	Reproduction in the patient with inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2013, 59, 285-97.	2.2	4
131	Flexible Sigmoidoscopy Does Not Significantly Increase Polyp and Cancer Detection Yield when Used to Supplement CT Colonography. <i>Digestion</i> , 2012, 85, 55-60.	2.3	3
132	Pregnancy related issues in inflammatory bowel disease: Evidence base and patients' perspective. <i>World Journal of Gastroenterology</i> , 2012, 18, 2600.	3.3	41
133	Mortality from Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1566-1572.	1.9	39
134	Patients' knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool (CCPKnow™). <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 57-63.	3.7	81
135	When to use biological agents in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1141-1149.	2.8	12
136	Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. <i>World Journal of Hepatology</i> , 2012, 4, 43.	2.0	28
137	Preferable Colonic Investigations for Isolated Abdominal Pain. <i>Southern Medical Journal</i> , 2011, 104, 170-173.	0.7	4
138	Long-term success of colonic stent insertion is influenced by indication but not by length of stent or site of obstruction. <i>International Journal of Colorectal Disease</i> , 2011, 26, 215-218.	2.2	30
139	Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 863-870.	2.4	52
140	Palliative Treatment of Dysphagia. , 2011, , 193-204.		0
141	<i>Helicobacter pylori</i> Eradication in Diabetic Patients: Still Far Off the Treatment Targets. <i>Southern Medical Journal</i> , 2010, 103, 975-976.	0.7	4
142	PTH-014...Does flexible sigmoidoscopy increase the polyp and cancer detection yield when used to supplement CT colonography?. <i>Gut</i> , 2010, 59, A128.1-A128.	12.1	0
143	An unusual inflammation of the colon. <i>Gut</i> , 2010, 59, 1393-1393.	12.1	1
144	T1223 Does Flexible Sigmoidoscopy Increase the Polyp and Cancer Detection Yield When Used to Supplement CT Colonography?. <i>Gastroenterology</i> , 2010, 138, S-515.	1.3	0

#	ARTICLE	IF	CITATIONS
145	W1472: Colonic Investigations for Isolated Abdominal Pain: Endoscopy or CT Colonography?. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB337.	1.0	0
146	W1473: Colonic Stents: Which Factors Influence Technical and Clinical Success?. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB337.	1.0	0
147	Is gastrointestinal endoscopy a risk factor for <i>Clostridium difficile</i> associated diarrhea?. <i>American Journal of Infection Control</i> , 2010, 38, 581-582.	2.3	10
148	T2063 Is Gastrointestinal Endoscopy a Risk Factor for <i>Clostridium difficile</i> Associated Diarrhoea?. <i>Gastroenterology</i> , 2009, 136, A-631.	1.3	0
149	Eosinophilic gastritis with idiopathic thrombocytopenic purpura: coincidence or association?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1425-1427.	1.6	2
150	Celiac Disease and the Heart. <i>Southern Medical Journal</i> , 2009, 102, 1001-1002.	0.7	0
151	Endoscopic Clearance of Common Bile Duct Stones: What Happens After? Value of Prophylactic Cholecystectomy. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB164-AB165.	1.0	0
152	Gastric Antral Vascular Ectasia (GAVE): An Update on Clinical Presentation, Pathophysiology and Treatment. <i>Digestion</i> , 2008, 77, 131-137.	2.3	136
153	Oesophageal stent insertion for palliation of dysphagia in a District General Hospital: experience from a case series of 137 patients. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 545-548.	0.5	24
154	Fracture of an esophageal stent: a rare but significant complication. <i>Endoscopy</i> , 2008, 40, E199-E199.	1.8	10
155	A good death certificate: improved performance by simple educational measures. <i>Postgraduate Medical Journal</i> , 2007, 83, 285-286.	1.8	36
156	Coffee ground vomit is difficult to identify. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 825.	1.6	2
157	Tablet induced dysphagia in oesophageal cancer. <i>Gut</i> , 2006, 55, 587-588.	12.1	2
158	Adherence to BSC adenoma surveillance guidelines will reduce colonoscopic workload. <i>Gut</i> , 2005, 54, 173-173.	12.1	10
159	Twitter debate: controversies in pregnancy in IBD and liver disease. <i>Frontline Gastroenterology</i> , 0, , flgastro-2021-101998.	1.8	0
160	The UK IBD Registry COVID-19 Risk Tool; Patient Generated Data Can Improve the Hospital Record. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
161	Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds <sc>IBD</sc> Steroids study. <i>Alimentary Pharmacology and Therapeutics</i> , 0, , .	3.7	3
162	Introduction to the DDS Mini-€Issue: œInflammatory Bowel Disease and Pregnancyœ. <i>Digestive Diseases and Sciences</i> , 0, , .	2.3	0